Candel Therapeutics Inc
For the period ended Sep 30, 2024. Filed Nov 14, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 14, 2024
CADL$9.35-1.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity (Deficit) (Unaudited)
Condensed Consolidated Statements of Stockholders’ Equity (Deficit)
(In thousands, except share amounts)
| COMMON STOCK · TREASURY STOCK · ADDITIONALPAID-IN · ACCUMULATED · STOCKHOLDERS’ | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| SHARES · AMOUNT · SHARES · AMOUNT · CAPITAL · DEFICIT · DEFICIT | ||||||||||
| Balance, December 31, 2023 | 29,213,627 | $290 | (122,608) | $(448) | $149,931 | $(137,028) | $12,745 | |||
| Options exercised | 731,169 | 7 | — | — | 1,312 | — | 1,319 | |||
| Stock-based compensation | — | — | — | — | 3,212 | — | 3,212 | |||
| Restricted stock unit vesting | 1,034,207 | 12 | — | — | (12) | — | — | |||
| Change in fair value of NC Ohio Trust Warrants | — | — | — | — | 856 | — | 856 | |||
| Sale of common stock, net of issuance costs | 1,268,741 | 13 | 7,702 | — | 7,715 | |||||
| Net loss | — | — | — | — | — | (41,104) | (41,104) | |||
| Balance, September 30, 2024 | 32,247,744 | $322 | (122,608) | $(448) | $163,001 | $(178,132) | $(15,257) | |||
| COMMON STOCK · TREASURY STOCK · ADDITIONALPAID-IN · ACCUMULATED · STOCKHOLDERS’ | ||||||||||
| SHARES · AMOUNT · SHARES · AMOUNT · CAPITAL · DEFICIT · DEFICIT | ||||||||||
| Balance, June 30, 2024 | 31,186,817 | $303 | (122,608) | $(448) | $157,659 | $(167,486) | $(9,972) | |||
| Options exercised | 46,296 | — | — | — | 103 | — | 103 | |||
| Stock-based compensation | — | — | — | — | 1,074 | — | 1,074 | |||
| Restricted stock unit vesting | 330,780 | 12 | — | — | (12) | — | — | |||
| Change in fair value of NC Ohio Trust Warrants | — | — | — | — | 110 | — | 110 | |||
| Sale of common stock, net of issuance costs | 683,851 | 7 | — | — | 4,067 | — | 4,074 | |||
| Net loss | — | — | — | — | — | (10,646) | (10,646) | |||
| Balance, September 30, 2024 | 32,247,744 | $322 | (122,608) | $(448) | $163,001 | $(178,132) | $(15,257) | |||
| COMMON STOCK · TREASURY STOCK · ADDITIONALPAID-IN · ACCUMULATED · STOCKHOLDERS’ | |||||||
|---|---|---|---|---|---|---|---|
| SHARES | AMOUNT | SHARES | AMOUNT | CAPITAL | DEFICIT | EQUITY | |
| Balance, December 31, 2022 | 29,042,418 | $290 | (122,608) | $(448) | $146,961 | $(99,089) | $47,714 |
| Stock-based compensation | — | — | — | — | 2,278 | — | 2,278 |
| Change in fair value of NC Ohio Trust Warrants | — | — | — | — | (126) | — | (126) |
| Net loss | — | — | — | — | — | (26,844) | (26,844) |
| Balance, September 30, 2023 | 29,042,418 | $290 | (122,608) | $(448) | $149,113 | $(125,933) | $23,022 |
| COMMON STOCK · TREASURY STOCK · ADDITIONALPAID-IN · ACCUMULATED · STOCKHOLDERS’ | |||||||
| SHARES | AMOUNT | SHARES | AMOUNT | CAPITAL | DEFICIT | EQUITY | |
| Balance, June 30, 2023 | 29,042,418 | $290 | (122,608) | $(448) | $148,427 | $(117,498) | $30,771 |
| Stock-based compensation | — | — | — | — | 735 | — | 735 |
| Change in fair value of NC Ohio Trust Warrants | — | — | — | — | (49) | — | (49) |
| Net loss | — | — | — | — | — | (8,435) | (8,435) |
| Balance, September 30, 2023 | 29,042,418 | $290 | (122,608) | $(448) | $149,113 | $(125,933) | $23,022 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.